Avience Biomedicals (NSE:AVIENCE) Marketable Securities: ₹7.4 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AVIENCE Avience Biomedicals Ltd NSE:AVIENCE
18 GF Score
Price ₹250.90
! 3 Warning Signs
View Full Analysis

What is Avience Biomedicals Marketable Securities?

Avience Biomedicals NSE:AVIENCE +1.17% 18 Marketable Securities is ₹7.4 Mil as of Mar. 2025. GuruFocus rates NSE:AVIENCE with a GF Score™ of 18/100. The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Avience Biomedicals's Marketable Securities for the quarter that ended in Mar. 2025 was ₹7.4 Mil.

Avience Biomedicals's annual Marketable Securities increased from Mar. 2023 (₹0.0 Mil) to Mar. 2024 (₹2.1 Mil) and increased from Mar. 2024 (₹2.1 Mil) to Mar. 2025 (₹7.4 Mil).

Avience Biomedicals  (NSE:AVIENCE) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Avience Biomedicals Marketable Securities Related Terms

Avience Biomedicals Marketable Securities Historical Data

* Premium members only.

The historical data trend for Avience Biomedicals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avience Biomedicals Marketable Securities Chart

Avience Biomedicals Annual Data
Trend Mar23 Mar24 Mar25
Marketable Securities
0.00 2.11 7.37

Avience Biomedicals Semi-Annual Data
Mar23 Mar24 Mar25
Marketable Securities 0.00 2.11 7.37
NSE:AVIENCE
18GF Score
Avience Biomedicals Ltd NSE:AVIENCE
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avience Biomedicals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of ₹7.4 Mil mean?
Avience Biomedicals (NSE:AVIENCE) has a Marketable Securities of ₹7.4 Mil as of Mar. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Avience Biomedicals and its competitors.
Is Avience Biomedicals' Marketable Securities too high?
Avience Biomedicals' current Marketable Securities is ₹7.4 Mil. Overall, Avience Biomedicals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Avience Biomedicals' Marketable Securities compare to ABT and SYK?
Avience Biomedicals' Marketable Securities of ₹7.4 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Avience Biomedicals and its competitors. Avience Biomedicals's current Marketable Securities is ₹7.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avience Biomedicals stock overvalued right now?
Avience Biomedicals (NSE:AVIENCE) has a current Marketable Securities of ₹7.4 Mil. The current Marketable Securities is ₹7.4 Mil. Avience Biomedicals' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Avience Biomedicals (NSE:AVIENCE), the current Marketable Securities is ₹7.4 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avience Biomedicals Business Description

Address C-11, Block-C, Community Centre, Unit No-2, 1st Floor, Janakpuri A-3, New Delhi, IND, 110058
Avience Biomedicals Ltd is a medical consumables company focused on the manufacturing of Vitro-Diagnostic (IVD) products and medical devices. Its product offerings include diagnostic solutions used for the detection of diseases, conditions, and infections across laboratory, healthcare, and home-use applications. The company operates in areas including molecular biotechnology, genomics, and diagnostic products, and also provides distribution services for medical technology products in India. Its revenue is generated from Manufactured Goods and Traded Goods and Services, which include the sale of Medical Devices and Consumables.
18GF Score

Get the complete analysis for NSE:AVIENCE

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹250.90
Price